Advertisement

pp 1-14 | Cite as

Depression

  • M. Axel WollmerEmail author
  • Michelle Magid
  • Tillmann H. C. Kruger
  • Eric Finzi
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

A series of clinical studies have shown that botulinum toxin can treat major depression. Subjects suffering from unipolar depression may experience a quick, strong, and sustained improvement in the symptoms of depression after a single glabellar treatment with botulinum toxin.

Preliminary data suggest that botulinum toxin therapy may also be effective in the treatment of other mental disorders characterized by an excess of negative emotions, such as borderline personality disorder.

The mood-lifting effect of botulinum toxin therapy is probably mediated by the interruption of a proprioceptive feedback loop from the facial musculature to the emotional brain.

Keywords

Embodiment Emotional proprioception Facial feedback hypothesis 

References

  1. Adelmann PK, Zajonc RB (1989) Facial efference and the experience of emotion. Annu Rev Psychol 40:249–280Google Scholar
  2. Al Abdulmohsen T, Kruger TH (2011) The contribution of muscular and auditory pathologies to the symptomatology of autism. Med Hypotheses 77:1038–1047Google Scholar
  3. Aydinlar EI, Dikmen PY, Kosak S et al (2017) OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. J Headache Pain 18:23Google Scholar
  4. Baumeister JC, Papa G, Foroni F (2016) Deeper than skin deep – the effect of botulinum toxin-A on emotion processing. Toxicon 118:86–90Google Scholar
  5. Beer K (2010) Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations. J Drugs Dermatol 9:27–30Google Scholar
  6. Boudreau GP, Grosberg BM, McAllister PJ et al (2015) Prophylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: an open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxiety. Int J Gen Med 9:79–86Google Scholar
  7. Brin MF, Boodhoo TI, Pogoda JM et al (2009) Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 61:961–970Google Scholar
  8. Caleo M, Schiavo G (2009) Central effects of tetanus and botulinum neurotoxins. Toxicon 54:593–599Google Scholar
  9. Carruthers A, Cohen JL, Cox SE et al (2007) Facial aesthetics: achieving the natural, relaxed look. J Cosmet Laser Ther 9(Suppl 1):6–10Google Scholar
  10. Cattaneo L, Pavesi G (2014) The facial motor system. Neurosci Biobehav Rev 38:135–159Google Scholar
  11. Chugh S, Chhabria A, Jung S et al (2018) Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract 24:15–20Google Scholar
  12. Cobo JL, Sole-Magdalena A, Menendez I et al (2017) Connections between the facial and trigeminal nerves: anatomical basis for facial muscle proprioception. JPRAS Open 12:9–18Google Scholar
  13. Cohen IV, Makunts T, Atayee R et al (2017) Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Sci Rep 7:1450Google Scholar
  14. Coles NA, Larsen JT, Lench HC (2019) A meta-analysis of the facial feedback literature: effects of facial feedback on emotional experience are small and variable. Psychol Bull 145:610–651Google Scholar
  15. Davis JI, Senghas A, Brandt F et al (2010) The effects of BOTOX injections on emotional experience. Emotion 10:433–440Google Scholar
  16. Demiryurek BE, Ertem DH, Tekin A et al (2016) Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci 37:1779–1784Google Scholar
  17. Dodick DW, Turkel CC, RE DG, PREEMPT Chronic Migraine Study Group et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50:921–936Google Scholar
  18. Ekman P, Friesen WV (1978) Facial action coding system: a technique for the measurement of facial movement. Consulting Psychologists Press, Palo AltoGoogle Scholar
  19. Ekman P, Levenson PW, Friesen WV (1983) Autonomic nervous system activity distinguishes among emotions. Science 212:1208–1210Google Scholar
  20. Finzi E, Rosenthal NE (2014) Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res 52:1–6Google Scholar
  21. Finzi E, Rosenthal NE (2016) Emotional proprioception: treatment of depression with afferent facial feedback. J Psychiatr Res 80:93–96Google Scholar
  22. Finzi E, Rosenthal NE (2019) Botulinum toxin therapy of social anxiety disorder: a case series. J Clin Psychopharmacol 39:410–412Google Scholar
  23. Finzi E, Wasserman E (2006) Treatment of depression with botulinum toxin A: a case series. Dermatol Surg 32:645–649Google Scholar
  24. Finzi E, Kels L, Axelowitz J et al (2018) Botulinum toxin therapy of bipolar depression: a case series. J Psychiatr Res 104:55–57Google Scholar
  25. Golden SA, Christoffel DJ, Heshmati M et al (2013) Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med 19:337–344Google Scholar
  26. Greden JF, Genero N, Price HL (1985) Agitation-increased electromyogram activity in the corrugator muscle region: a possible explanation of the “Omega sign”? Am J Psychiatry 142:348–351Google Scholar
  27. Guerzoni S, Pellesi L, Baraldi C et al (2015) Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. J Headache Pain 17:48Google Scholar
  28. Guerzoni S, Pellesi L, Baraldi C et al (2017) Long-term treatment benefits and prolonged efficacy of OnabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol 8:586Google Scholar
  29. Havas DA, Glenberg AM, Gutowski KA et al (2010) Cosmetic use of botulinum toxin-a affects processing of emotional language. Psychol Sci 21:895–900Google Scholar
  30. Heckmann M, Teichmann B, Schroder U et al (2003) Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol 49:213–216Google Scholar
  31. Hennenlotter A, Dresel C, Castrop F et al (2009) The link between facial feedback and neural activity within central circuitries of emotion-new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex 19:537–542Google Scholar
  32. Hexsel D, Brum C, Siega C et al (2013) Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg 39:1088–1096Google Scholar
  33. Ibragić S, Matak I, Dračić A et al (2016) Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats. Neurosci Lett 617:213–217Google Scholar
  34. Kim MJ, Neta M, Davis FC et al (2014) Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design. Biol Mood Anxiety Disord 4:11Google Scholar
  35. Kollewe K, Escher CM, Wulff DU et al (2016) Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm 123:533–540Google Scholar
  36. Kruger TH, Wollmer MA (2015) Depression--an emerging indication for botulinum toxin treatment. Toxicon 107:154–157Google Scholar
  37. Kruger TH, Magid M, Wollmer MA (2016) Can botulinum toxin help patients with borderline personality disorder? Am J Psychiatry 173:940–941Google Scholar
  38. Lewis MB, Bowler PJ (2009) Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol 8:24–26Google Scholar
  39. Li Y, Liu J, Liu X (2019) Antidepressant-like action of single facial injection of botulinum neurotoxin A is associated with augmented 5-HT levels and BDNF/ERK/CREB pathways in mouse brain. Neurosci Bull 35(4):661–672Google Scholar
  40. Maasumi K, Thompson NR, Kriegler JS (2015) Effect of OnabotulinumtoxinA injection on depression in chronic migraine. Headache 55:1218–1224Google Scholar
  41. Magid M, Reichenberg JS, Poth PE et al (2014) Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 75:837–844Google Scholar
  42. Magid M, Finzi E, Kruger TH et al (2015) Treating depression with botulinum toxin: a pooled analysis of randomized controlled trials. Pharmacopsychiatry 48:205–210Google Scholar
  43. Marchand-Pauvert V, Aymard C, Giboin LS et al (2013) Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol 591:1017–1029Google Scholar
  44. Matsuo K, Ban R, Hama Y et al (2015) Eyelid opening with trigeminal proprioceptive activation regulates a brainstem arousal mechanism. PLoS One 10:e0134659Google Scholar
  45. Molina B, Grangier Y, Mole B (2015) Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study. J Eur Acad Dermatol Venereol 29:1382–1388Google Scholar
  46. Parsaik AK, Mascarenhas SS, Hashmi A et al (2016) Role of botulinum toxin in depression. J Psychiatr Pract 22:99–110Google Scholar
  47. Schwartz GE, Fair PL, Salt P et al (1976) Facial muscle patterning to affective imagery in depressed and nondepressed subjects. Science 192:489–491Google Scholar
  48. Sommer B, Zschocke I, Bergfeld D et al (2003) Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg 29:456–460Google Scholar
  49. Wollmer MA, de Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581Google Scholar
  50. Wollmer MA, Kalak N, Jung S et al (2014) Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial. Front Psych 5:36Google Scholar
  51. Wollmer MA, Neumann I, Magid M et al (2018) Shrink that frown! Botulinum toxin therapy is lifting the face of psychiatry. G Ital Dermatol Venereol 153:540–548Google Scholar
  52. Zamanian A, Ghanbari Jolfaei A, Mehran G et al (2017) Efficacy of botox versus placebo for treatment of patients with major depression. Iran J Public Health 46:982–984Google Scholar
  53. Zhang H, Zhang H, Wei Y et al (2017) Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study. Int J Neurosci 127:285–290Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • M. Axel Wollmer
    • 1
    Email author
  • Michelle Magid
    • 2
  • Tillmann H. C. Kruger
    • 3
  • Eric Finzi
    • 4
  1. 1.Asklepios Clinic North–Ochsenzoll, Asklepios Campus Hamburg, Medical Faculty, Semmelweis UniversityHamburgGermany
  2. 2.Dell Medical School, University of Texas at AustinAustinUSA
  3. 3.Department of Psychiatry, Social Psychiatry and PsychotherapyMedical School HannoverHannoverGermany
  4. 4.Department of Psychiatry and Behavioral SciencesGeorge Washington School of MedicineWashingtonUSA

Personalised recommendations